Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of US$2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock. The pre-funded warrants are being sold at a public offering price of US$2.449 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. In addition, Geron has granted the underwriters a 30-day option to purchase up to an additional 12,131,444 shares of its common stock, less underwriting discounts and commissions. The offering is expected to close on or about January 10, 2023, subject to the satisfaction of customary closing conditions.
Latham & Watkins LLP represents the underwriters in the offering with a corporate deal team led by Bay Area partner Brian Cuneo and Orange County partner Ross McAloon, with associates Natalie Robertson, Jake Walsh, Kennedy Holmes, Allison (AJ) Blair, and Jacob Kempf. Advice was also provided on regulatory matters by Bay Area partner Heather Deixler, Washington, D.C. partner Elizabeth Richards, Bay Area counsel Betty Pang, and Washington, D.C. counsel Chad Jennings; on intellectual property matters by Bay Area partner Judith Hasko and Bay Area/San Diego partner Christopher Hazuka, with associates Robert Yeh and Kristina Funahashi; on tax matters by Bay Area partner Grace Lee, with associate Gregory Conyers; and with additional assistance by Los Angeles/Century City partner Joshua Hamilton and associate Eric Pettis.